Many of the most potent currently available agents for cancer chemotherapy interact directly in one way or another with DNA. Among those causing DNA damage are crosslinking and alkylating agents like cisplatinum and cyclophosphamide (Roberts and Pascoe, 1972; Ramonas et al., 1981) , which form covalent bonds with DNA, drugs which form complexes or intercalate by hydrophobic interaction and/or hydrogen bond formation like actinomycin D (Farber et al., 1960) , or drugs acting as anti-metabolites competing with native bases like 5-fluorouracil (5-Fu) or fludarabine (Cheson, 1992) . Intercalation is reported to be a common feature of anthracyclines and acridine derivatives, including agents such as doxorubicin, dauno-rubicin, mitoxantrone and nitracrine (DiMarco, 1975; Denny, 1989; Konopa, 1990) , which have proven to be clinically highly active against a variety of tumours and have been shown to cause cell death by subsequent inhibition of DNA synthesis (Piestrzeniewcz et al., 1987; Mazerska et al., 1990; Burr-Furlong et al., 1978) . The ability to intercalate is a useful property of some drugs (Hernandez et al., 1995) ; however, DNA binding by intercalation alone may not be sufficient for anti-tumour activity. It is widely thought that the most active anti-tumour DNA intercalators work by stabilising the cleavable DNAprotein complex formed by the enzyme topoisomerase II, resulting in lethal strand breaks (Drlica and Franco, 1988) .
The most widely used intercalating agent so far, doxorubicin, is known to induce cardiotoxicity by free radical formation from the doxorubicin redox cycle (Workman and Graham, 1993) , which causes severe side-effects in doxorubicin chemotherapy (Weiss et al., 1986) . Therefore, a series of imidazoacridinones has recently been developed in an effort to generate antineoplastic agents, which combine common characteristics of acridines and anthracyclines essential for anti-cancer activity, such as planar structure and polycyclic nucleus, with higher affinity to target DNA and resistance to production of radicals by enzymatic reduction (Cholody et al., 1990a) . Diethylamino groups thought to be capable of binding electrostatically to phosphate moieties of DNA were introduced (Cholody et al., 1990b) , and a pyrazole ring was added to increase the electron density of the 7t ring system preventing free radical generation (Cholody et al., 1990a) . Preliminary screening results for several of these compounds showed cytotoxic activity towards HeLaS3 cells and anti-tumour activity against P388 leukaemia (Cholody et al., 1990a,b) , B16 melanoma and colon adenocarcinoma C26 and C38 (Kusnierczyk et al., 1994) in mice.
In this article, we report the preclinical evaluation of two novel acridine derivatives, imidazoacridinones C1310 and C1311 (Figure 1 ). Studies by LH Patterson (personal communication) have shown that these compounds do not form free oxygen radicals. This study was designed to examine the in vitro and in vivo activity of these clinical candidate compounds against colon tumours and to investigate further the biological and biochemical properties in order to provide information that might aid the decisionmaking process. Hill et al., 1992; Collard et al., 1995) .
Materials and methods
Drug treatment and assessment of activity Drugs were given as i.p. bolus injections in therapeutic doses as assessed before treatment. 5-FU was administered at 125 mg kg-' body weight (70% LD10), C1310 and C1311 were given in doses of 25, 50 and 100 mg kg-' in the MAC1SA tumour system and 100 mg kg-1 in the MAC29 model respectively. HT29-bearing mice were treated with 50 and 100 mg kg -' C1311. Control mice received vehicle (normal saline solution) only. A minimum group size of six animals was used. Treatment commenced when tumours could be measured reliably by calipers, i.e. had reached minimum dimensions of 4 x 5 mm. Tumour growth was followed by serial caliper measurements and body weight was recorded simultaneously. Anti-tumour activity was assessed by tumour volume (Geran et al., 1972) and growth delay was determined by comparison of the median time taken to reach a relative tumour volume (RTV) of 2 in treated (T) vs control (C) MAC29 and HT29 tumours or RTV of 5 for MAC1SA tumours. The significance of these results was tested applying Mann-Whitney non-parametric statistics. Results were also expressed as percentage growth delay in which a positive number indicated that the treated tumour reached the RTV of 2 and 5, respectively, more slowly than the control tumour, and as optimum percentage T/C (day), a parameter used by the NCI in vivo screening programme. Percentage treated/control was calculated by dividing the median treated tumour weight by the median control tumour weight on each observation day and multiplying by 100. The optimum %T/C and the day on which it occurred was recorded (Dykes et al., 1992; Hernandez et al., 1995) . An optimum %T/C of greater than 40 was considered inactive.
Fluorescence microscopy Intracellular distribution of C1310 and C1311 was studied by fluorescence microscopy using a Vickers M 17 microscope (Optivision, Ossett, UK). Since the compounds have a fluorochromic structure, they are highly fluorescent with an excitation maximum at about 340 nm (emission 520 nm). Approximately 5 x 106 HT29 colon carcinoma cells were treated with C1310 and C1311 for 10, 30 and 60 min at IC50 and TGI concentrations. Cells were then trypsinised, transferred into 15 ml tubes, washed twice with phosphate-buffered saline (PBS) and kept at 4°C. Localisation of fluorescence was examined for each sample/time point and documented in a series of fluorescence photomicrographs.
DNA binding analysis DNA-binding properties of the imidazoacridinone derivative, C 1311, in comparison with the known DNA binder, doxorubicin, were tested by spectrophotometric titration, thermal denaturation and Scatchard plot studies following procedures described elsewhere (Double and Brown, 1975; Plumbridge et al., 1978; Islam et al., 1985) . CT (Calf thymus) DNA [Sigma type I; 2.5 x 10-3 M (P), concentration determined from the equation E (P)260= 6600] and drug solutions (5 x 10-I M) were prepared in isotonic Tris-HCl buffer, pH 7.4, and measurements performed using a PerkinElmer Lambda-5 UV/VIS spectrophotometer with a fitted Peltier temperature programmer, PTP-6 (Perkin-Elmer, Beaconsfield, UK). Thermal denaturation of CT-DNA was measured at a DNA -drug ratio of 10:1 and the final DNAdrug ratio for spectrophotometric titration experiments was at least 20:1. The compounds tested obeyed Lambert -Beer's law over the concentration range used. DNA-binding parameters, K and n, were estimated by linear regression analysis of Scatchard plot data transformation (Double and Brown, 1975; Plumbridge et al., 1978) . (Table II) . As shown in Figure 2a , 100 mg kg-' C1311 produced a similar growth delay in MAC29 tumours to 5-FU at a dose of 125 mg kg-'. The human xenograft HT29 also responded well to C1311 treatment (Figure 2b ), but the drug was less well tolerated in nude mice causing an isolated animal death (Table II) . No acute toxicity was observed in NMRI mice at the doses used (25, 50 and 100 mg kg-'). Although showing similar in vitro activity to C1311, C1310 was not very active in both murine colorectal cancer models tested. On the contrary, low doses of 25 mg even appeared slightly to increase tumour growth (Table II) . Data depicted in Figure 2a and b and Table II have been confirmed in another independent experiment in each case.
Uptake and distribution of C1310/C1311 into cells
The uptake of C1310/C1311 into living cells was studied in vitro by fluorescence microscopy and is illustrated in Figure  3 . C1311 and C1310 drug uptake and internalisation was followed in HT29 colon carcinoma cells over several time points at concentrations inducing 50% and 100% growth inhibition (Table I) . We found that C1310 and C1311 fluorescence was rapidly detectable in the nuclear regions of HT29 cells at both concentrations tested. observed as early as 10 min after treatment at IC5s (e.g. 0.5 gM in HT29) and intensified with increasing concentration and exposure periods. Interestingly, as depicted in Figure  3 for C1311 in HT29 cells, the compounds were not only seen to accumulate in nuclei but also in discrete cytoplasmic structures in nearly all the cells treated.
DNA binding studies Spectrophotometric titration studies revealed a clear isosbestic point for C1311 at 456 nm ilrnax 425 nm), which is indicative of the presence of only two species of ligand, a single distinct bound form of drug in addition to free drug (Double and Brown, 1975) . Such a linear binding equilibrium suggests the existence of a single class of internal binding sites for the interaction of the compound with CT-DNA (Blake and Peacock, 1968) . Doxorubicin, used as standard agent under the same conditions, showed an isosbestic point at 545 nm (A.max 477 nm).
The estimated association constant for formation of bound ligand -DNA complex, K, derived from Scatchard plot analysis gave a K value of 3.1 x 106 M-l with n=0.35 in the case of C1311. For doxorubicin, K was 2.36x 106 Mwith n=0.31. The n value represents the number of sites available for drug binding per DNA phosphate (Blake and Peacock, 1968 ). An n value of about 0.3 would imply that a drug molecule fits into the CT-DNA approximately every 3 basepairs. Higher values obtained for C1311 in comparison with doxorubicin could reflect a higher binding affinity and binding frequency of C1311 to CT-DNA and might be explained by a better fit of the diethylamino side-chain of C1311 (Figure 1) to the DNA helix compared with the longer amino sugar residue of doxorubicin.
The DNA-binding properties of C1311 were further reflected in the stabilisation of CT-DNA (melting point 73.5°C) to thermal denaturation. A Tm value (temperature at which the half-maximum of absorbance was observed) for C1311 was determined at 86°C, resulting in a ATm of 12.5°C. Tm for doxorubicin was found to be 88.5°C, giving a ATTm of 15°C. When a molecule binds into the DNA helix, the macromolecule is stabilised and more energy is required to separate the strands, thus increased DNA melting points (Tm values) can be considered indicative of the previously described drug-DNA interactions (Neidle et al., 1987 (Double and Brown, 1975; Plumbridge and Brown, 1979) .
The difference between concentrations needed to achieve total growth inhibition among the colorectal tumour cell lines examined (Table I) is of interest and might be explained either by variance in growth rates or in the DNA repair enzyme status of these cells. Determination of both IC50 and TGI is a useful exercise as it might facilitate selection of the most appropriate human cell line for in vivo study. Steep dose -response curves with small differences between IC50 and TGI values, e.g. HT29 (Table I) , might predict for in vivo activity.
Although binding into DNA is likely to be involved initially in the effects C1310 and C1311 impose on cells, additional mechanisms might well be operative and contribute to the observed differences in growth inhibition and cell death induced by these imidazoacridinones. Indeed, a cascade of secondary drug effects, such as DNA cross-linking after metabolic activation or topoisomerase inhibition and DNA fragmentation following the initial distortion of DNA integrity by intercalation, have previously been discussed for closely related classes of compounds (Konopa, 1990; Denny, 1989; Skladanowski and Konopa, 1993) . Very recent studies have demonstrated that C1310 and C1311 inhibit the catalytic activity of purified topoisomerase II and stimulate the formation of cleavable complexes in vitro (Skladanowski et al., 1996). Although no major differences between C1310 and C1311 were observed in vitro, C1310 is strikingly less active in vivo than C1311 (Table II) . The poor response of the colorectal in vivo tumour models to C1310, which is distinguished by just 9 AM Burger et al 1374 one methyl group from C1311 (Figure 1 ), may be caused by differences in pharmacokinetics. In this context, the in vitro data demonstrate that duration of exposure is important for activity and suggest that TGI levels need to be present for at least 1 h to achieve significant effects. The pharmacokinetic behaviour of the compounds is currently under detailed investigation and will be reported elsewhere. Future work will also include a study of the influence of route of administration and dosage scheduling on the anti-tumour activity of C1311. However, the data presented in this study indicate that C1311, in particular, has good activity against the model systems examined. In addition to the in vivo activity against colon carcinomas, the lack of free oxygen radical production suggests that this compound has potential for clinical development.
